论文部分内容阅读
取健康“O”型供血者的PBMC经PHA预刺激后制成PHA-LAK,其表型以CD3~+、CD8~+为主,IL-2R表达水平、增殖能力、体外存活时间及细胞毒活性等均明显优于常规LAK。用该PHA-LAK(PHA预刺激的LAK细胞)与rIL-2(TGP-3,日本,武田)治疗60例实体瘤患者(肾癌24例,肝癌、恶性淋巴瘤、结肠癌各5例,肺癌12例,其它恶性肿瘤9例)。Ⅰ、Ⅱ期临床试验结果表明,本PHA-LAK/IL-2疗法毒副作用甚轻或无,对肾癌、肝癌、恶性淋巴瘤的近期疗效较好,从而为肿瘤的继承性细胞免疫治疗开拓了新路。
The PBMCs from healthy “O” donors were pre-stimulated with PHA to make PHA-LAK with a phenotype of CD3+, CD8+, IL-2R expression, proliferation, in vitro survival, and cytotoxicity. The activities are all significantly better than conventional LAK. The PHA-LAK (PHA pre-stimulated LAK cells) and rIL-2 (TGP-3, Japan, Takeda) treatment of 60 patients with solid tumors (24 cases of renal cell carcinoma, liver cancer, malignant lymphoma, 5 cases of colon cancer, 12 cases of lung cancer, 9 cases of other malignant tumors). Phase I and II clinical trials have shown that the PHA-LAK/IL-2 therapy has very low or no toxic side effects, and has a good short-term effect on renal cancer, liver cancer, and malignant lymphoma, thus opening up the possibility of inherited cellular immunotherapy for tumors. A new road.